Showing 1291-1300 of 10904 results for "".
- Difamilast Ointment Shows Week 4 Benefits in Pediatric and Adult Atopic Dermatitis Trialshttps://practicaldermatology.com/news/difamilast-ointment-shows-week-4-benefits-in-pediatric-and-adult-atopic-dermatitis-trials/2488681/Difamilast 1% ointment was associated with higher rates of Investigator’s Global Assessment (IGA) success than vehicle at week 4 in separate phase 3 studies involving adults and children with atopic dermatitis (AD), according to an integrated review presented at the 2026 Fall Clinical Dermatology
- Barzolvolimab Responses Persist After Treatment in Selected Chronic Urticaria Patientshttps://practicaldermatology.com/news/barzolvolimab-responses-persist-after-treatment-in-selected-chronic-urticaria-patients/2488679/Nearly 7 in 10 evaluable patients with antihistamine-refractory chronic spontaneous urticaria (CSU) who achieved well-controlled disease after a year of barzolvolimab maintained control 24 weeks later, according to a post hoc analysis of a phase 2 trial presented at the 2026 Fall Clinical Dermato
- Hyperpigmentation Review Examines Treatment Strategies and Evidence Gaps in Skin of Colorhttps://practicaldermatology.com/news/hyperpigmentation-review-examines-treatment-strategies-and-evidence-gaps-in-skin-of-color/2488677/A literature review presented at the 2026 Fall Clinical Dermatology Conference examined mechanisms and treatment strategies for hyperpigmentation disorders, emphasizing persistent gaps in evidence involving patients with skin of color. Susan Taylor, MD, of the University of Pennsylvania, a
- Pediatric Nemolizumab Study Reports Improvements in Atopic Dermatitis Through 52 Weekshttps://practicaldermatology.com/news/pediatric-nemolizumab-study-reports-improvements-in-atopic-dermatitis-through-52-weeks/2488676/Weight-based nemolizumab administered with topical therapy was associated with improvements in skin lesions and itch in children aged 2 to 11 years with moderate-to-severe atopic dermatitis (AD), according to phase 2 findings presented at the 2026 Fall Clinical Dermatology Conference. Lawr
- GLP-1 Medication Use Shows No Apparent Impact on Icotrokinra Outcomes in Phase 3 Psoriasis Analysishttps://practicaldermatology.com/news/glp-1-medication-use-shows-no-apparent-impact-on-icotrokinra-outcomes-in-phase-3-psoriasis-analysis/2488675/Concomitant use of glucagon-like peptide-1 (GLP-1)–based medications was not associated with an apparent difference in icotrokinra efficacy, safety, or pharmacokinetics among patients with plaque psoriasis, according to pooled post hoc analyses of the phase 3 ICONIC clinical trial program present
- Comparison Examines GEP Performance Against Melanoma SLNB Risk Thresholdshttps://practicaldermatology.com/news/comparison-examines-gep-performance-against-melanoma-slnb-risk-thresholds/2488674/A comparison of two prospective studies evaluating gene expression profiling (GEP) tests combined with clinicopathologic factors found differences in their ability to identify patients with cutaneous melanoma at low risk for sentinel lymph node (SLN) positivity.1
- New Imaging Approach Shows High Agreement in Mohs Margin Assessment: Studyhttps://practicaldermatology.com/news/2-new-imaging-approach-shows-high-agreement-in-mohs-margin-assessment/2488673/A recent Modern Pathology study reported found that ex vivo fluorescence confocal microscopy (EVFCM) achieved high overall diagnostic accuracy in assessing surgical margins during Mohs surgery for nonmelanoma skin cancer (NMSC). EVFCM Shows Strong Agreement With Histopathology i
- Switching From Dupilumab to Upadacitinib Associated With No Skin Flares in Atopic Dermatitis Analysishttps://practicaldermatology.com/news/switching-from-dupilumab-to-upadacitinib-associated-with-few-flares-in-atopic-dermatitis-analysis/2488672/Patients with moderate-to-severe atopic dermatitis (AD) who switched from dupilumab to upadacitinib monotherapy following inadequate treatment response experienced no observed skin lesion flares and infrequent itch flares over 16 weeks, according to a post hoc analysis pres
- TOGETHER-PsO: Combination Therapy Shows Expanded Molecular Response by Week 12https://practicaldermatology.com/news/together-pso-combination-therapy-shows-expanded-molecular-response-by-week-12/2488671/Eli Lilly and Company announced Phase 3 data from the TOGETHER-PsO trial indicating broader immune and metabolic biomarker changes with concomitant ixekizumab (Taltz) and tirzepatide (Zepbound) compared with ixekizumab alone in adults with moderate-to-severe plaque psoriasis and obesity or overwe
- Telehealth Intervention Improves Sun Protection Behaviors in Children of Melanoma Survivorshttps://practicaldermatology.com/news/telehealth-intervention-improves-sun-protection-behaviors-in-children-of-melanoma-survivors/2488649/A family-based telehealth intervention significantly improved sun-protective behaviors among children of melanoma survivors but failed to reduce sunburn over time, according to findings from a randomized study published in JAMA Dermatology. Thye study sought to evaluate whether th